By inhibiting Src, verapamil and dasatinib overcome multidrug resistance via increased expression of Bim and decreased expressions of MDR1 and survivin in human multidrug-resistant myeloma cells

Leukemia Research

Volumn 38, Issue 1, 2014, Pages 121-130

  Tsubaki, Masanobu ^a   Komai, Makiko ^a   Itoh, Tatsuki ^b   Imano, Motohiro ^b   Sakamoto, Kotaro ^a   Shimaoka, Hirotaka ^a   Takeda, Tomoya ^a   Ogawa, Naoki ^a,c   Mashimo, Kenji ^a,d   Fujiwara, Daiichiro ^a,d   Mukai, Junji ^c   Sakaguchi, Katsuhiko ^d   Satou, Takao ^b   Nishida, Shozo ^a  

^a KINKI UNIVERSITY   (Japan)

^b KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c Izumi Municipal Hospital   (Japan)

^d JAPANESE RED CROSS WAKAYAMA MEDICAL CENTER   (Japan)

Author keywords

Bim; Dasatinib; Drug resistance; MDR1; Multiple myeloma; Src; Survivin; Verapamil

Indexed keywords

BIM PROTEIN; DASATINIB; MULTIDRUG RESISTANCE PROTEIN 1; PROTEIN TYROSINE KINASE; SURVIVIN; VERAPAMIL;

ARTICLE; CONTROLLED STUDY; DRUG SENSITIVITY; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; GENE REPRESSION; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; MULTIPLE MYELOMA; MYELOMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 84890567462     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2013.10.017     Document Type: Article

References (40)

1. Kyle R.A., Rajkumar S.V. Multiple myeloma. Blood 2008, 111:2962-2972.
2. Elliott T., Sethi T. Integrins and extracellular matrix: a novel mechanism of multidrug resistance. Expert Rev Anticancer Ther 2002, 2:449-459.
3. Bosch I., Croop J. P-glycoprotein multidrug resistance and cancer. Biochim Biophys Acta 1996, 1288:F37-F54.
4. Eckford P.D., Sharom F.J. ABC efflux pump-based resistance to chemotherapy drugs. Chem Rev 2009, 109:2989-3011.
5. Mossink M.H., van Zon A., Scheper R.J., Sonneveld P., Wiemer E.A. Vaults: a ribonucleoprotein particle involved in drug resistance?. Oncogene 2003, 22:7458-7467.
6. LaCasse E.C., Baird S., Korneluk R.G., MacKenzie A.E. The inhibitors of apoptosis (IAPs) and their emerging role in cancer. Oncogene 1998, 17:3247-3259.
7. Tamm I., Wang Y., Sausville E., Scudiero D.A., Vigna N., Oltersdorf T., et al. IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res 1998, 58:5315-5320.
8. Yang J., Liu X., Bhalla K., Kim C.N., Ibrado A.M., Cai J., et al. Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondria blocked. Science 1997, 275:1129-1132.
9. Johnstone R.W., Ruefli A.A., Lowe S.W. Apoptosis: a link between cancer genetics and chemotherapy. Cell 2002, 108:153-164.
10. Reed J.C. Bcl-2 and the regulation of programmed cell death. J Cell Biol 1994, 124:1-6.
11. Wang J.L., Liu D., Zhang Z.J., Shan S., Han X., Srinivasula S.M., et al. Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells. Proc Natl Acad Sci USA 2000, 97:7124-7129.
12. Shangary S., Johnson D.E. Peptides derived from BH3 domains of Bcl-2 family members: a comparative analysis of inhibition of Bcl-2, Bcl-x(L) and Bax oligomerization, induction of cytochrome c release, and activation of cell death. Biochemistry 2002, 41:9485-9495.
13. Reed J.C. Dysregulation of apoptosis in cancer. J Clin Oncol 1999, 17:2941-2953.
14. Tsubaki M., Satou T., Itoh T., Imano M., Komai M., Nishinobo M., et al. Overexpression of MDR1 and survivin, and decreased Bim expression mediate multidrug-resistance in multiple myeloma cells. Leuk Res 2012, 36:1315-1322.
15. Pajeva I., Wiese M. Molecular modeling of phenothiazines and related drugs as multidrug resistance modifiers: a comparative molecular field analysis study. J Med Chem 1998, 41:1815-1826.
16. Litman T., Druley T.E., Stein W.D., Bates S.E. From MDR to MXR: new understanding of multidrug resistance systems, their properties and clinical significance. Cell Mol Life Sci 2001, 58:931-959.
17. Chiu L.Y., Ko J.L., Lee Y.J., Yang T.Y., Tee Y.T., Sheu G.T. L-type calcium channel blockers reverse docetaxel and vincristine-induced multidrug resistance independent of ABCB1 expression in human lung cancer cell lines. Toxicol Lett 2010, 192:408-418.
18. Coluccia A.M., Cirulli T., Neri P., Mangieri D., Colanardi M.C., Gnoni A., et al. Validation of PDGFRbeta and c-Src tyrosine kinases as tumor/vessel targets in patients with multiple myeloma: preclinical efficacy of the novel, orally available inhibitor dasatinib. Blood 2008, 112:1346-1356.
19. Sandur S.K., Pandey M.K., Sung B., Aggarwal B.B. 5-Hydroxy-2-methyl-1,4-naphthoquinone, a vitamin K3 analogue, suppresses STAT3 activation pathway through induction of protein tyrosine phosphatase, SHP-1: potential role in chemosensitization. Mol Cancer Res 2010, 8:107-118.
20. Liu Y.Y., Gupta V., Patwardhan G.A., Bhinge K., Zhao Y., Bao J., et al. Glucosylceramide synthase upregulates MDR1 expression in the regulation of cancer drug resistance through cSrc and beta-catenin signaling. Mol Cancer 2010, 11:145.
21. Nowak D., Boehrer S., Hochmuth S., Trepohl B., Hofmann W., Hoelzer D., et al. Src kinase inhibitors induce apoptosis and mediate cell cycle arrest in lymphoma cells. Anticancer Drugs 2007, 18:981-995.
22. Woods N.T., Yamaguchi H., Lee F.Y., Bhalla K.N., Wang H.G. Anoikis, initiated by Mcl-1 degradation and Bim induction, is deregulated during oncogenesis. Cancer Res 2007, 67:10744-10752.
23. Majumder S., Dutta P., Mukherjee P., Datta E.R., Efferth T., Bhattacharya S., et al. Reversal of drug resistance in P-glycoprotein-expressing T-cell acute lymphoblastic CEM leukemia cells by copper N-(2-hydroxy acetophenone) glycinate and oxalyl bis (N-phenyl) hydroxamic acid. Cancer Lett 2006, 244:16-23.
24. Liu F., Xie Z.H., Cai G.P., Jiang Y.Y. The effect of survivin on multidrug resistance mediated by P-glycoprotein in MCF-7 and its adriamycin resistant cells. Biol Pharm Bull 2007, 30:2279-2283.
25. Meister S., Frey B., Lang V.R., Gaipl U.S., Schett G., Schlötzer-Schrehardt U., et al. Calcium channel blocker verapamil enhances endoplasmic reticulum stress and cell death induced by proteasome inhibition in myeloma cells. Neoplasia 2010, 12:550-561.
26. Kim L.C., Song L., Haura E.B. Src kinases as therapeutic targets for cancer. Nat Rev Clin Oncol 2009, 6:587-595.
27. Guarino M. Src signaling in cancer invasion. J Cell Physiol 2010, 223:14-26.
28. Schlessinger J. New roles for Src kinases in control of cell survival and angiogenesis. Cell 2000, 100:293-296.
29. Lu J., Tan M., Huang W.C., Li P., Guo H., Tseng L.M., et al. Mitotic deregulation by survivin in ErbB2-overexpressing breast cancer cells contributes to Taxol resistance. Clin Cancer Res 2009, 15:1326-1334.
30. Ramasamy K., Khatun H., Macpherson L., Caley M.P., Sturge J., Mufti G.J., et al. Fluorescence-based experimental model to evaluate the concomitant effect of drugs on the tumour microenvironment and cancer cells. Br J Haematol 2012, 157:564-579.
31. Guerrouahen B.S., Futami M., Vaklavas C., Kanerva J., Whichard Z.L., Nwawka K., et al. Dasatinib inhibits the growth of molecularly heterogeneous myeloid leukemias. Clin Cancer Res 2010, 16:1149-1158.
32. Nam S., Williams A., Vultur A., List A., Bhalla K., Smith D., et al. Dasatinib (BMS-354825) inhibits Stat5 signaling associated with apoptosis in chronic myelogenous leukemia cells. Mol Cancer Ther 2007, 6:1400-1405.
33. Konig H., Copland M., Chu S., Jove R., Holyoake T.L., Bhatia R. Effects of dasatinib on SRC kinase activity and downstream intracellular signaling in primitive chronic myelogenous leukemia hematopoietic cells. Cancer Res 2008, 68:9624-9633.
34. Baumgartner C., Gleixner K.V., Peter B., Ferenc V., Gruze A., Remsing Rix L.L., et al. Dasatinib inhibits the growth and survival of neoplastic human eosinophils (EOL-1) through targeting of FIP1L1-PDGFRalpha. Exp Hematol 2008, 36:1244-1253.
35. Hallaert D.Y., Jaspers A., van Noesel C.J., van Oers M.H., Kater A.P., Eldering E. c-Abl kinase inhibitors overcome CD40-mediated drug resistance in CLL: implications for therapeutic targeting of chemoresistant niches. Blood 2008, 112:5141-5149.
36. Mamidipudi V., Cartwright C.A. A novel pro-apoptotic function of RACK1: suppression of Src activity in the intrinsic and Akt pathways. Oncogene 2009, 28:4421-4433.
37. Neri P., Ren L., Azab A.K., Brentnall M., Gratton K., Klimowicz A.C., et al. Integrin β7-mediated regulation of multiple myeloma cell adhesion, migration, and invasion. Blood 2011, 117:6202-6213.
38. Clapham D.E. Calcium signaling. Cell 2007, 131:1047-1058.
39. Liu C.C., Leclair P., Yap S.Q., Lim C.J. The membrane proximal KxGFFKR motif of α-integrin mediates chemoresistance. Mol Cell Biol 2013, (in press).
40. 2+ channel blocker, in human epidermoid carcinoma A431 cells. Biochem Pharmacol 2007, 73:943-953.